FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128049587> ?p ?o ?g. }

• W2128049587 endingPage "192" @default.
• W2128049587 startingPage "167" @default.
• W2128049587 abstract "Coagulation disorders are common in cancer patients. In patients with solid tumors, a low-grade activated coagulation can result in systemic and cerebral arterial or venous thrombosis. Cancer treatments may also contribute to this coagulopathy, which usually, but not exclusively, occurs in the setting of advanced malignant disease. There may be TIAs or cerebral infarctions. Because of the widespread distribution of cerebral thromboses, there may be a superimposed encephalopathy; sometimes this is the only sign. Concurrent systemic thrombosis is present in many patients and is a useful clue to the diagnosis. In cerebral venous occlusion, the initial symptom is usually a headache. Except for cerebral intravascular coagulation that is unassociated with NBTE, neuriomaging studies usually demonstrate one or more parenchymal infarctions. MRI or MRV may demonstrate venous thrombosis. The laboratory evidence of coagulopathy is difficult to distinguish from the asymptomatic coagulopathy that often accompanies advanced cancer, and the test results must be interpreted cautiously. NBTE can be diagnosed by transesophageal echocardiography. There is no established treatment for the thrombotic coagulopathy associated with cancer, but anticoagulation should be considered. In leukemia and lymphoma, the coagulopathy is typically acute DIC that can lead to systemic and brain hemorrhages. It is especially common in acute myelogenous leukemias. The clinical signs of cerebral hemorrhage are fulminant and may be fatal. The bleeding usually occurs in the brain or subdural compartment, and rarely in the subarachnoid space. The diagnosis can be suspected by the clinical setting and by systemic thrombosis or hemorrhage. It can be established by examination of the peripheral smear, the platelet count, and tests of coagulation function. Therapy of acute DIC is controversial and should be individualized for the clinical setting. Cerebrovascular disorders can complicate metastatic or primary tumor in the brain, skull, dura, or leptomeninges. The clinical signs of infarction are indistinguishable from other causes of stroke, except that tumor-related venous occlusion will usually first produce signs of increased intracranial pressure. The diagnosis of tumor-related infarction can usually be established by neuroimaging studies that show infarction and may show extracerebral sites of tumor. CSF examination is useful in diagnosing leptomeningeal metastasis. A search for lung or cardiac tumor should be performed when embolic tumor infarction is suspected. Primary or metastatic tumors in the brain or dura may hemorrhage, producing the initial clinical signs of the brain tumor or a change in chronic signs induced by the tumor. There are helpful clues to a neoplastic hemorrhage on brain CT or MRI scans. The brain hemorrhage may require evacuation and the underlying tumor will usually require additional antineoplastic treatment. Hyperleukocytosis (extreme elevation of the cell count) in acute myelogenous leukemia is a less common cause of brain hemorrhage in recent years because of improved methods to lower the cell count. Cerebral arterial or venous thrombosis is sometimes the result of cancer therapy. The attribution of thrombosis to chemotherapy in many published cases is only speculative, because carefully conducted prospective studies that include investigation for other thrombotic causes are not available. The best-known associations with thrombosis are L-asparaginase, which is typically used in the induction therapy of acute lymphocytic leukemia, and combination hormonal therapy and chemotherapy for breast cancer. Radiation to the head and neck, typically administered for head and neck epithelial cancers or lymphoma, may result in delayed carotid atherosclerosis. The distribution of stenosis or occlusion is within the radiation portal and is typically more extensive than is atherosclerosis that develops in the absence of radiation. Small clinical series suggest that surgical treatment is equally effective as in nonirradiated carotid atherosclerosis. In children, the cerebral vessels can be affected by brain radiation resulting in stenosis or occlusion. Brain hemorrhages can result from chemotherapy effects on the hemostatic system or a microangiopathic anemia. Hemorrhages from radiation-induced vascular abnormalities are rare. Opportunistic infections, especially fungal infections, can complicate cancer or its treatment. Septic cerebral emboli may result in focal cerebral signs, seizures, or encephalopathy. Sometimes there is an associated hemorrhagic vasculitis or cerebritis. Rarely, mycotic aneurysms may bleed. A high index of suspicion is needed to diagnose fungal infection because of the difficulty in culturing the organism from the blood or CSF. A clinician can usually establish the cause of stroke in the cancer patient by performing a careful review of the clinical setting--including the type and extent of cancer and the type of antineoplastic therapy--in which the stroke occurred. Systemic thrombosis, embolism, or hemorrhage can be a clue to the cause, and appropriate neuroimaging and coagulation studies to aid in the diagnosis are available. Therapy may ameliorate symptoms or prevent further episodes. The identification of one of these unusual stroke syndromes that leads to the diagnosis of an occult and treatable cancer can be particularly rewarding." @default.
• W2128049587 created "2016-06-24" @default.
• W2128049587 creator A5003243219 @default.
• W2128049587 date "2003-02-01" @default.
• W2128049587 modified "2023-09-29" @default.
• W2128049587 title "Cerebrovascular complications in cancer patients" @default.
• W2128049587 cites W106515720 @default.
• W2128049587 cites W1492005248 @default.
• W2128049587 cites W1496217454 @default.
• W2128049587 cites W183219228 @default.
• W2128049587 cites W1881424050 @default.
• W2128049587 cites W1909615309 @default.
• W2128049587 cites W1963835606 @default.
• W2128049587 cites W1964596170 @default.
• W2128049587 cites W1969937189 @default.
• W2128049587 cites W1971889901 @default.
• W2128049587 cites W1976009700 @default.
• W2128049587 cites W1976024649 @default.
• W2128049587 cites W1976677371 @default.
• W2128049587 cites W1977271246 @default.
• W2128049587 cites W1981864796 @default.
• W2128049587 cites W1982003717 @default.
• W2128049587 cites W1982921859 @default.
• W2128049587 cites W1985414900 @default.
• W2128049587 cites W1987254135 @default.
• W2128049587 cites W1987534718 @default.
• W2128049587 cites W1988624024 @default.
• W2128049587 cites W1989570486 @default.
• W2128049587 cites W1989596179 @default.
• W2128049587 cites W1995266436 @default.
• W2128049587 cites W1995369709 @default.
• W2128049587 cites W1996841186 @default.
• W2128049587 cites W1999983540 @default.
• W2128049587 cites W2013946999 @default.
• W2128049587 cites W2014065719 @default.
• W2128049587 cites W2020147043 @default.
• W2128049587 cites W2021502678 @default.
• W2128049587 cites W2023063243 @default.
• W2128049587 cites W2026654523 @default.
• W2128049587 cites W2027335241 @default.
• W2128049587 cites W2030718871 @default.
• W2128049587 cites W2032450469 @default.
• W2128049587 cites W2033498238 @default.
• W2128049587 cites W2038630471 @default.
• W2128049587 cites W2040291479 @default.
• W2128049587 cites W2042564421 @default.
• W2128049587 cites W2043023302 @default.
• W2128049587 cites W2045770232 @default.
• W2128049587 cites W2046313368 @default.
• W2128049587 cites W2046614198 @default.
• W2128049587 cites W2050196300 @default.
• W2128049587 cites W2060990622 @default.
• W2128049587 cites W2063268568 @default.
• W2128049587 cites W2065336608 @default.
• W2128049587 cites W2065468887 @default.
• W2128049587 cites W2073988409 @default.
• W2128049587 cites W2080818169 @default.
• W2128049587 cites W2081791117 @default.
• W2128049587 cites W2083122826 @default.
• W2128049587 cites W2084720179 @default.
• W2128049587 cites W2085202845 @default.
• W2128049587 cites W2086806618 @default.
• W2128049587 cites W2088178265 @default.
• W2128049587 cites W2094360632 @default.
• W2128049587 cites W2101649726 @default.
• W2128049587 cites W2105362446 @default.
• W2128049587 cites W2110908941 @default.
• W2128049587 cites W2116751182 @default.
• W2128049587 cites W2117667713 @default.
• W2128049587 cites W2119914962 @default.
• W2128049587 cites W2121156212 @default.
• W2128049587 cites W2141557567 @default.
• W2128049587 cites W2144488005 @default.
• W2128049587 cites W2149062346 @default.
• W2128049587 cites W2157858114 @default.
• W2128049587 cites W2158351882 @default.
• W2128049587 cites W2160289222 @default.
• W2128049587 cites W2166191925 @default.
• W2128049587 cites W2171119585 @default.
• W2128049587 cites W2227853740 @default.
• W2128049587 cites W2228075402 @default.
• W2128049587 cites W2334200141 @default.
• W2128049587 cites W4242762640 @default.
• W2128049587 doi "https://doi.org/10.1016/s0733-8619(02)00066-x" @default.
• W2128049587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1758430" @default.
• W2128049587 hasPublicationYear "2003" @default.
• W2128049587 type Work @default.
• W2128049587 sameAs 2128049587 @default.
• W2128049587 citedByCount "184" @default.
• W2128049587 countsByYear W21280495872012 @default.
• W2128049587 countsByYear W21280495872013 @default.
• W2128049587 countsByYear W21280495872014 @default.
• W2128049587 countsByYear W21280495872015 @default.
• W2128049587 countsByYear W21280495872016 @default.
• W2128049587 countsByYear W21280495872017 @default.
• W2128049587 countsByYear W21280495872018 @default.
• W2128049587 countsByYear W21280495872019 @default.
• W2128049587 countsByYear W21280495872020 @default.

• next